Population | New incident | Mortality | ||
---|---|---|---|---|
Females | Male | Females | Male | |
WHO South-East Asia | 40.8 % | 59.2 % | 38.3 % | 61.7 % |
WHO Western Pacific | 40.6 % | 59.4 % | 43.1 % | 56.9 % |
WHO Americas | 44 % | 56 % | 41.5 % | 58.5 % |
WHO East Mediterranean | 43.5 % | 56.5 % | 40.1 % | 59.9 % |
WHO Europe | 41.7 % | 58.3 % | 42.1 % | 57.9 % |
WHO Africa | 42.3 % | 57.7 % | 43.9 % | 56.1 % |
all WHO regions | 42.1 % | 57.9 % | 41.5 % | 58.5 % |
Acquired syndromes/Genetic disorders | Type of leukemia | Mutation | |
---|---|---|---|
Down Syndrome | |||
Down Syndrome (DS) | ALL/AML |
|
|
DNA repair gene syndromes and chromosomal instability syndromes | |||
Fanconi anemia (FA) | MDS/AML | ||
Bloom’s syndrome (BS) |
ALL AML |
||
Ataxia-telangiectasia (AT) | ALL | ||
Constitutional Mismatch Repair Deficiency (CMMRD) | ALL |
|
|
Robertson translocation(RT) | ALL | ||
Tumor suppressor gene syndromes | |||
Li-Fraumeni syndrome(LFS) | ALL | ||
Neurofibromatosis (NF1) | ALL AML (JMML) | ||
Beckwith-Wiedemann syndrome (BWS) | ALL | ||
Pure familial leukemia | |||
Acquired monosomy 7 | MDS/AML | ||
Hereditary platelet disorders (HPDs) | MDS/AML |
|
|
Bone marrow failure syndromes | |||
Shwachman-Diamond syndrome (SDS) | AML | ||
Diamond Blackfan anemia (DBA) | MDS/AML | ||
Congenital amegakaryocytic thrombocytopenia (CAMT) | MDS/AML | ||
Cyclic neutropenia (CyN) | MDS/AML | ||
Severe congenital neutropenia (SCN) | AML | ||
Amegakaryocytic thrombocytopenia (AMT) | MDS/AML | ||
Hereditary platelet disorders (HPDs) | MDS/AML |
|
|
Aplastic anemia (AA) | MDS/AML |
|
AML with defining genetic abnormalities |
AML with RUNX1::RUNX1T1 Fusion |
AML with CBFB::MYH11 Fusion |
Acute promyelocytic leukaemia with PML::RARA Fusion |
AML with KMT2A rearrangement |
AML with DEK::NUP214 Fusion |
AML with MECOM rearrangement |
AML with RBM15::MRTFA Fusion |
AML with NUP98 rearrangement |
AML with other (rare) defined genetic alterations |
AML with NPM1 mutation |
AML with CEBPA mutation |
AML defined by differentiation |
AML with minimal differentiation |
AML without maturation |
AML with maturation |
Acute myelomonocytic leukemia |
Acute monoblastic/monocytic leukemia |
Pure erythroid leukemia |
Acute megakaryoblastic leukemia |
Acute basophilic leukemia |
B-ALL with t(12;21)(p13.2;q22.1)/ETV6::RUNX1 |
B-ALL. hyperdiploid |
B-ALL. low hypodiploid |
B-ALL. near haploid |
B-ALL with t(5;14)(q31.1;q32.3)/IL3::IGH |
B-ALL with t(1;19)(q23.3;p13.3)/TCF3::PBX1 |
B-ALL. BCR::ABL1–like, ABL-1 class rearranged |
B-ALL. BCR::ABL1–like, JAK-STAT activated |
B-ALL. BCR::ABL1–like, NOS (undefined) |
B-ALL with iAMP21 |
B-ALL with MYC rearrangement |
B-ALL with DUX4 rearrangement |
B-ALL with MEF2D rearrangement |
B-ALL with ZNF384(362) rearrangement |
B-ALL with NUTM1 rearrangement |
B-ALL with HLF rearrangement |
B-ALL with UBTF::ATXN7L3/PAN3,CDX2 (“CDX2/UBTF”) |
B-ALL with mutated IKZF1 N159Y |
B-ALLwith mutated PAX5 P80R |
Provisional entity: B-ALL. ETV6::RUNX1-like |
Provisional entity: B-ALL. with PAX5 alteration |
Provisional entity: B-ALL. with mutated ZEB2 (p.H1038R)/IGH::CEBPE |
Provisional entity: B-ALL. ZNF384 rearranged-like |
Provisional entity: B-ALL. KMT2A rearranged-like |
B-ALL, NOS (undefined) |
T-ALL |
Early T-cell precursor ALLwith BCL11B rearrangement |
Early T-cell precursor ALL. NOS |
T-ALL. NOS |
Provisional entity: natural killer cell ALL |